Citations

Mayo Clinic

Showing 10 of 108523 citations.

Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cells
Chitta, Kasyapa S., Paulus, Aneel , Akhtar, Sharoon , Blake, Maja K. , Caulfield, Thomas R. , Novak, Anne J. , Ansell, Stephen M. , Advani, Pooja , Sher, Taimur , Linder, Stig , Chanan‐Khan, Asher , Chitta, Kasyapa, Ailawadhi, Sikander , Caulfield, Thomas R , Paulus, Aneel

British Journal of Haematology | February 17, 2015 | Volume: 169 | Issue: 3 | Pages: 377-390

10.1111/bjh.13304 | PMID 25691154 Get It

SummaryDeubiquitinase enzymes (DUBs) of the proteasomal 19S regulatory particle are emerging as important therapeutic targets in several malignancies. Here we demonstrate that inhibition of two proteasome‐associated DUBs (USP14 and UCHL5) with the small molecule DUB inhibitor b‐AP15, results in apoptosis of human Waldenström macroglobulinaemia (WM) cell lines and primary patient‐derived WM tumour cells. Importantly, b‐AP15 produced proteotoxic stress and apoptosis in WM cells that have acquired resistance to the proteasome inhibitor bortezomib. In silico modelling identified protein residues that were critical for the binding of b‐AP15 with USP14 or UCHL5 and proteasome enzyme activity assays confirmed that b‐AP15 does not affect the proteolytic capabilities of the 20S proteasome β‐subunits. In vitro toxicity from b‐AP15 appeared to result from a build‐up of ubiquitinated proteins and activation of the endoplasmic reticulum stress response in WM cells, an effect that also disrupted the mitochondria. Focused transcriptome profiling of b‐AP15‐treated WM cells revealed modulation of several genes regulating cell stress and NF‐κB signalling, the latter whose protein translocation and downstream target activation was reduced by b‐AP15 in vitro. This is the first report to define the effects and underlying mechanisms associated with inhibition of USP14 and UCHL5 DUB activity in WM tumour cells.
Taking the Slower Pathway
Asirvatham, Samuel J. , Stevenson, William G. , Asirvatham, Samuel J

Circulation: Arrhythmia and Electrophysiology | February 17, 2015 | Volume: 8 | Issue: 1 | Pages: 236-238

10.1161/circep.115.002641 | PMID 25691558 Get It

Troubleshooting Implantable Cardioverter-Defibrillator Sensing Problems II
Swerdlow, Charles D. , Asirvatham, Samuel J. , Ellenbogen, Kenneth A. , Friedman, Paul A. , Asirvatham, Samuel J , Ellenbogen, Kenneth A

Circulation: Arrhythmia and Electrophysiology | February 17, 2015 | Volume: 8 | Issue: 1 | Pages: 212-220

10.1161/circep.114.002514 | PMID 25691555 Get It

Cardiac Regeneration
Martinez‐Fernandez, Almudena

Circulation: Cardiovascular Genetics | February 17, 2015 | Volume: 8 | Issue: 1 | Pages: 211-212

10.1161/circgenetics.114.000981 | PMID 25691691 Get It

Dynamic ultrasonography can demonstrate the mechanism of the palmaris profundus in carpal tunnel syndrome
Cesmebasi, Alper , Spinner, Robert J. , Smith, Jay , Martinoli, Carlo

Clinical Anatomy | February 17, 2015 | Volume: 28 | Issue: 4 | Pages: 428-430

10.1002/ca.22507 | PMID 25691145 Get It

Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management
Pardanani, Animesh

American Journal of Hematology | February 17, 2015 | Volume: 90 | Issue: 3 | Pages: 250-262

10.1002/ajh.23931 | PMID 25688753 Get It

Disease overview: Systemic mastocytosis (SM) results from a clonal proliferation of abnormal mast cells (MC) in one or more extracutaneous organs.Diagnosis: The major criterion is presence of multifocal clusters of morphologically abnormal MC in the bone marrow. Minor diagnostic criteria include elevated serum tryptase level, abnormal MC expression of CD25 and/or CD2, and presence of KITD816V.Risk stratification: The 2008 World Health Organization classification of SM has been shown to be prognostically relevant. Classification of SM patients into indolent SM (ISM), aggressive SM (ASM), SM associated with a clonal non‐MC lineage disease (SM‐AHNMD), and mast cell leukemia (MCL) subgroups is a useful first step in establishing prognosis.Management: SM treatment is generally palliative. ISM patients have a normal life expectancy and receive symptom‐directed therapy; infrequently, cytoreductive therapy may be indicated for refractory symptoms. ASM patients have disease‐related organ dysfunction; interferon‐α (+/−corticosteroids) can control dermatological, hematological, gastrointestinal, skeletal, and mediator‐release symptoms, but is hampered by poor tolerability. Similarly, cladribine has broad therapeutic activity, with particular utility when rapid MC debulking is indicated; the main toxicity is myelosuppression. Imatinib has a therapeutic role in the presence of an imatinib‐sensitive KIT mutation or in KITD816‐unmutated patients. Treatment of SM‐AHNMD is governed primarily by the non‐MC neoplasm; hydroxyurea has modest utility in this setting; there is a role for allogeneic stem cell transplantation in select cases.Investigational Drugs: Recent data confirms midostaurin's significant anti‐MC activity in patients with advanced SM. Am. J. Hematol. 90:251–262, 2015. © 2015 Wiley Periodicals, Inc.
Effect of Varenicline on Smoking Cessation Through Smoking Reduction
Ebbert, Jon O. , Hughes, John R. , West, Robert , Rennard, Stephen I. , Russ, Cristina , McRae, Thomas, Treadow, Joan, Yu, Ching‐Ray, Dutro, Michael P. , Park, Peter W.

JAMA | February 17, 2015 | Volume: 313 | Issue: 7 | Pages: 687

10.1001/jama.2015.280 | PMID 25688780 Get It

Contemporary applications of frontal sinus trephination: A systematic review of the literature
Patel, Alpen B., Cain, Rachel B. , Lal, Devyani

The Laryngoscope | February 17, 2015 | Volume: 125 | Issue: 9 | Pages: 2046-2053

10.1002/lary.25206 | PMID 25688730 Get It

Our objective was to perform a systematic review of the literature on contemporary indications and outcomes for frontal sinus trephination and present an illustrative case of an endoscopically assisted repair of a subcutaneous frontal sinus fistula by trephination technique. PubMed and Ovid databases were used as data sources. A systematic review of the English literature was completed to review reports of frontal trephination from 1980 to 2014. Articles meeting inclusion criteria for inflammatory and noninflammatory indications were reviewed. Articles were systematically reviewed and graded by evidence‐based medicine level. An illustrative case from our institution is then presented. The systematic review identified 2,621 published studies. Thirty‐eight studies were identified for inclusion. The indications, techniques, outcomes, safety, and complications were reviewed for noninflammatory and inflammatory conditions. There were 32 retrospective case series, reports, or cohort studies (level 4), four systematic reviews (level 3), one prospective analysis (level 3), and one meta‐analysis (level 2). Due to the heterogeneity of study cases and inclusion criteria, a meta‐analysis was not feasible. We also present a novel closure of an anterior skull base defect resulting in a subcutaneous fistula with use of a frontal trephination approach. The frontal sinus trephination should not be regarded as a procedure of the past, as it useful in the armamentarium of the modern sinus and skull base surgeon. This approach provides access for instrumentation for hard‐to‐reach frontal sinus disease either purely through a trephination approach or as a supplementation to the transnasal endoscopic approach. Evidence supporting frontal sinus trephination is of levels 2, 3, and 4.Level of EvidenceNALaryngoscope, 125:2046–2053, 2015
Novel biodegradable poly(propylene fumarate)-co-poly( l -lactic acid) porous scaffolds fabricated by phase separation for tissue engineering applications
Liu, Xifeng , Waletzki, Brian E., Yaszemski, Michael J. , Lu, Lichun , Miller, A. Lee , Miller, Alan Lee

RSC Advances | February 17, 2015 | Volume: 5 | Issue: 27 | Pages: 21301-21309

10.1039/c5ra00508f | PMID 26989483 Get It

Three-dimensional polymer scaffolds with interconnected porous structures were fabricated by thermally induced phase separation of novel biodegradable poly(propylene fumarate)- co -poly( l -lactic acid).